RE: Value27 Oct 2022 00:45
3Bn in revenue does not mean avacta are getting 3bn. The 3Bn figure is also new to me too I must have missed that update I was re-reading the last presentation slides which said:
AVA6000 market opportunity
• Doxorubicin has been a standard of care treatment for advanced soft tissue sarcoma
(ASTS) for 40 years.
• Its use is limited by serious dose limiting toxicities such as cardio-toxicity and
myelosuppression.
• Despite this the global market for this generic drug is $1bn.
• AVA6000: The estimated market size (peak sales) of a safer/more efficacious form of
doxorubicin in just three indications (ASTS, breast and ovarian cancer), in the US/EU
alone, is $1.5bn* pa.
• A licensing agreement with a large pharma partner should deliver 10% royalties on sales
to Avacta.